Trial Profile
Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 20 Mar 2020
Price :
$35
*
At a glance
- Drugs Rotigotine (Primary)
- Indications Anxiety; Parkinson's disease
- Focus Therapeutic Use
- Acronyms ANXPD
- 18 Oct 2019 Status changed from recruiting to discontinued.
- 04 Jan 2019 Planned End Date changed from 1 Jan 2019 to 1 Dec 2019.
- 04 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Oct 2019.